Article
Biochemistry & Molecular Biology
Masato Mashimo, Akane Morozumi, Akari Nobeyama, Misato Kanzaki, Shigeru Negi, Jiro Kato, Joel Moss, Atsuo Nomura, Takeshi Fujii
Summary: Parthanatos is a programmed cell death process mediated by PARP1, which inhibits endocytosis by binding to Rab5, leading to cell starvation and death.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Yves Pommier, Anish Thomas
Summary: ADCs are effective in delivering cytotoxic agents to tumors, and two ADCs delivering TOP1 poisons have been FDA-approved. A recent study introduced a TOP1-anti B7-H4 ADC that showed synergistic effect with a PARP1-selective inhibitor.
CLINICAL CANCER RESEARCH
(2023)
Article
Biology
Sridevi Challa, Keun W. Ryu, Amy L. Whitaker, Jonathan C. Abshier, Cristel Camacho, W. Lee Kraus
Summary: In this study, PAR Trackers were developed and characterized as highly sensitive tools for detecting ADPR in various experimental and biological systems, providing greater temporal and spatial precision.
Article
Oncology
William P. Tew, Christina Lacchetti, Elise C. Kohn
Summary: ASCO Rapid Recommendations Updates provide revisions to select ASCO guideline recommendations based on new and practice-changing data. The goal is to disseminate updated recommendations in a timely manner to inform health practitioners and the public on the best available cancer care options.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Editorial Material
Biochemistry & Molecular Biology
Michael S. Cohen
Summary: ADP-ribosylation is a crucial post-translational modification, involving MAR and PAR. Researchers have identified distinct MAR and PAR readers using a chemical biology approach.
Article
Oncology
Emad Matanes, Vanessa M. Lopez-Ozuna, David Octeau, Tahira Baloch, Florentin Racovitan, Amandeep Kaur Dhillon, Roy Kessous, Oded Raban, Liron Kogan, Shannon Salvador, Susie Lau, Walter H. Gotlieb, Amber Yasmeen
Summary: The study showed that PARG inhibition can complement PARP inhibition in the treatment of ovarian cancer, especially in the presence of homologous recombination defects. PARG inhibitor alone or in combination with PARPi or Cisplatin can reduce cell migration and induce cell death.
FRONTIERS IN ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
David Hutin, Karoline Alvik Hagen, Peng Shao, Kim Sugamori, Denis M. Grant, Jason Matthews
Summary: PARP7 is an important regulator of the immune system, and is involved in intestinal inflammation. Loss of PARP7 impairs immune response to colon inflammation, possibly due to its role in IFN-I signaling rather than AHR signaling.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Immunology
Cassandra L. R. van Doorn, Sanne A. M. Steenbergen, Kimberley V. Walburg, Tom H. M. Ottenhoff
Summary: The inhibition of PARP has been shown to reduce the levels of Mycobacterium tuberculosis (Mtb) in human macrophages, indicating that PARP could be a potential target for developing innovative host-directed therapies against Mtb.
FRONTIERS IN IMMUNOLOGY
(2021)
Editorial Material
Oncology
Keun-Yeong Jeong, Haejun Lee
Summary: Chemotherapeutic regimens for pancreatic cancer are limited as it is typically diagnosed in advanced stages and hard to detect early symptoms. Mutations in BRCA leading to reduced susceptibility to conventional chemotherapies offer a new perspective, emphasizing the key role of PARP-1 in genomic instability.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY
(2021)
Article
Pathology
Fabio Aimi, Holger Moch, Peter Schraml, Michael O. Hottiger
Summary: The study used a new anti-ADP-ribose antibody to assess ADPR levels in various cancer types, finding predominant cytoplasmic ADPR staining. Strong cytoplasmic ADPR levels were associated with better overall survival in specific breast and ovarian cancer types. Different cyADPR staining patterns correlated with early tumor stages and absence of lymph node metastasis, potentially influencing response rates to PARP inhibitors.
Article
Biochemistry & Molecular Biology
Divakar Vishwanath, Swamy S. Girimanchanaika, Dukanya Dukanya, Shobith Rangappa, Ji-Rui Yang, Vijay Pandey, Peter E. Lobie, Basappa Basappa
Summary: In this study, a series of oxadiazole-based compounds were synthesized and found to exhibit potential PARP-1 targeting activity in mammary carcinoma cells. These compounds demonstrated comparable anti-tumor and anti-proliferation activities to Olaparib.
Review
Hematology
Christina-Nefeli Kontandreopoulou, Panagiotis T. Diamantopoulos, Despina Tiblalexi, Nefeli Giannakopoulou, Nora-Athina Viniou
Summary: PARP1 plays a crucial role in DNA damage repair and cancer progression, with its inhibitors showing promise in a wider range of patients. Ongoing clinical trials suggest the potential of PARPis in targeted treatment of various hematologic malignancies, highlighting their effectiveness in overcoming resistance.
Review
Pharmacology & Pharmacy
Ruihong Dong, Ting Ding, Zhengyu Li
Summary: Ovarian cancer is a common reproductive system tumor with increasing incidence in China. Poly(ADP-ribose) polymerase inhibitor (PARPi) targets DNA repair enzyme PARP to kill tumor cells, particularly those with HR dysfunction. PARPi has been widely used in clinical practice for maintenance therapy of advanced ovarian epithelial cancer. However, the development of intrinsic or acquired drug resistance to PARPi has become a significant clinical problem. This review summarizes the mechanisms of PARPi resistance and current progress on PARPi-based combination strategies.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Medicine, General & Internal
Lingchao Liu, Bahetiyaer Huwatibieke, Xiaoqing Lu, Dexin Li, Haiyan Dong, Jingyan Han, Weizhen Zhang, Yi Zhang, Yin Li
Summary: TiPARP plays a crucial role in regulating adipogenesis in both white and brown adipocytes, influencing lipid accumulation and cell maturity, providing a potential strategy for combating obesity.
JOURNAL OF TRANSLATIONAL INTERNAL MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Tarek El-Hamoly, Zoltan Hajnady, Mate Nagy-Penzes, Edina Bakondi, Zsolt Regdon, Mate A. Demeny, Katalin Kovacs, Csaba Hegedus, Sahar S. Abd El-Rahman, Eva Szabo, Jozsef Maleth, Peter Hegyi, Laszlo Virag
Summary: PARP1 plays an important role in the pathogenesis of chronic pancreatitis, and the PARP inhibitor olaparib has protective effects in a mouse model of CP by reducing inflammation and fibrosis. This suggests that PARP inhibitors may be promising candidates for treating both acute and chronic pancreatitis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Hematology
Krzysztof Madry, Karol Lis, Pierre Fenaux, David Bowen, Argiris Symeonidis, Moshe Mittelman, Reinhard Stauder, Jaroslav Cermak, Guillermo Sanz, Eva Hellstrom-Lindberg, Saskia Langemeijer, Luca Malcovati, Ulrich Germing, Mette Skov Holm, Agnes Guerci-Bresler, Dominic Culligan, Laurence Sanhes, Ioannis Kotsianidis, Corine van Marrewijk, Simon Crouch, Theo de Witte, Alex Smith
Summary: Information on causes of death and the impact of myelodysplastic syndromes (MDS) on survival in patients with lower-risk MDS is limited. This study shows that MDS and its related complications play a crucial role in the outcome of patients with lower-risk MDS.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Konstantinos Liapis, Vasileios Papadopoulos, Charalambos Pontikoglou, George Vrachiolias, Emily Stavroulaki, Alexandra Kourakli, Vasileios Lazaris, Athanasios G. Galanopoulos, Menelaos Papoutselis, Sotirios G. Papageorgiou, Panagiotis T. Diamantopoulos, Vassiliki Pappa, Nora-Athina Viniou, Dimitris Tsokanas, Theodoros P. Vassilakopoulos, Eleftheria Hatzimichael, Eleni Bouronikou, Maria Ximeri, Aekaterini Megalakaki, Panagiotis Zikos, Panayiotis Panayiotidis, Maria Dimou, Stamatis Karakatsanis, Maria Papaioannou, Stavros Papadakis, Anna Vardi, Flora Kontopidou, Nikolaos Harchalakis, Ioannis Adamopoulos, Argiris Symeonidis, Helen A. Papadaki, Ioannis Kotsianidis
Article
Hematology
Vasiliki Papadopoulou, Jacqueline Schoumans, Ilaria Scarpelli, Sabine Blum
Summary: The gene encoding for transcription factor ETV6 frequently undergoes mutations in hematologic neoplasms. The role of ETV6 in normal hematopoiesis is unclear, but its loss of function may contribute to tumorigenesis. Deletions at the ETV6-locus (12p13) are rare but recurrent in myeloid neoplasms, while ETV6 translocations are even rarer but seem to have defining consequences on phenotype. The mechanisms underlying these lesions are still unknown.
ACTA HAEMATOLOGICA
(2023)
Letter
Hematology
Panagiotis T. Diamantopoulos, Elena Solomou, Argiris Symeonidis, Vasiliki Pappa, Ioannis Kotsianidis, Athanasios Galanopoulos, Charalampos Pontikoglou, Achilles Anagnostopoulos, George Vassilopoulos, Panagiotis Zikos, Eleftheria Hatzimichael, Maria Papaioannou, Aekaterini Megalakaki, Theodoros Vassilakopoulos, Maria Dimou, Dimitrios Tsokanas, Menelaos-Konstantinos Papoutselis, Sotirios Papageorgiou, Alexandra Kourakli, Helen Papadaki, Panayiotis Panayiotidis, Nora-Athina Viniou
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Letter
Hematology
Efstathios Kastritis, Evangelos Terpos, Argiris Symeonidis, Vasiliki Labropoulou, Sosana Delimpasi, Katia Mancuso, Elena Zamagni, Eirini Katodritou, Elena Rivolti, Marie-Christine Kyrtsonis, Maria Roussou, Despina Fotiou, Foteini Theodorakakou, Ioannis Ntanasis-Stathopoulos, Evdoxia Hatjiharissi, Nikolaos Kanellias, Magdalini Migkou, Giorgos Cheliotis, Kyriaki Manousou, Maria Gavriatopoulou, Meletios A. Dimopoulos
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Letter
Pharmacology & Pharmacy
Vasiliki Papadopoulou, Nils Degrauwe, Laurent Arthur Decosterd, Thierry Buclin, Anne Cairoli
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
(2023)
Letter
Oncology
Ioannis Mitroulis, Vasileios Papadopoulos, Eleftheria Lamprianidou, Peter Mirtschink, Konstantinos Liapis, Kalliopi Zafeiropoulou, Alexandra Kourakli, Theodoros Moysiadis, Menelaos Papoutselis, George Vrachiolias, Argiris Symeonidis, Ioannis Kotsianidis
BLOOD CANCER JOURNAL
(2023)
Editorial Material
Oncology
Argiris Symeonidis, Ulrich Germing
FRONTIERS IN ONCOLOGY
(2023)
Editorial Material
Medicine, General & Internal
Mariam Markouli, Alexia Saridaki, Nora-Athina Viniou, Nefeli Giannakopoulou, Eleftheria Lakiotaki, Penelope Korkolopoulou, Panagiotis Diamantopoulos
Summary: This report describes a rare case of plasmablastic extramedullary plasmacytoma that was found on abdominal ultrasound and MRI and led to cholecystectomy in a 61-year-old patient. Concurrent bone plasmacytoma was also discovered through FDG PET-CT. The patient is currently undergoing chemotherapy and preparing for autologous stem cell transplantation.
Article
Microbiology
Eirini A. Apostolidi, Maria N. Gamaletsou, Maria Arapaki, John V. Asimakopoulos, Panagiotis Diamantopoulos, Sofia Zafeiratou, Diamantis Kofteridis, Maria Pagoni, Maria Kotsopoulou, Michael Voulgarelis, Nikolaos V. Sipsas
Summary: Iron overload may not be an independent risk factor for invasive fungal infections among patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome in transformation.
Article
Hematology
Vasiliki Papadopoulou, Giulia Schiavini
Summary: In our clinical practice, we have consistently observed a prolongation of activated partial thromboplastin time (aPTT) in patients treated with asparaginase. However, this phenomenon is largely unreported in the literature and guidelines, and is not widely known to clinicians. In this study, we investigated the changes in clotting factors, fibrinogen, and D-dimers before and after asparaginase administration in a small cohort of patients. We found significant reductions in FIX and FXI levels after treatment, confirming previous observations. Our findings suggest that the prolonged aPTTs may be caused by disturbed factor synthesis rather than consumption.
JOURNAL OF BLOOD MEDICINE
(2023)
Article
Genetics & Heredity
Stavroula Siamoglou, Ruben Boers, Maria Koromina, Joachim Boers, Anna Tsironi, Theodora Chatzilygeroudi, Vasileios Lazaris, Evgenia Verigou, Alexandra Kourakli, Wilfred F. J. van IJcken, Joost Gribnau, Argiris Symeonidis, George P. Patrinos
Summary: Myelodysplastic syndromes (MDS) are a group of hematological malignancies characterized by ineffective hematopoiesis, cytogenetic abnormalities, and a high risk of transformation to acute myeloid leukemia (AML). This study used methylated DNA sequencing (MeD-seq) to identify potential epigenomic targets associated with MDS subtypes. The results identified differentially methylated CpG islands, transcription start sites, and post-transcriptional start sites within the PCDHG and ZNF gene families. These findings provide important insights into the epigenomic component of MDS pathogenesis and the potential for targeted drug treatment.
Review
Hematology
Panagiotis T. Diamantopoulos, Amalia Anastasopoulou, Maria Dimopoulou, Michalis Samarkos, Helen Gogas
Summary: Patients with sickle cell disease (SCD) often suffer from anemia, inflammation, and vaso-occlusion, while treatment with hydroxyurea (HU) can reduce complications and increase survival. However, the use of BRAF and MEK inhibitors (BRAF/MEKi) for melanoma treatment has been linked to inflammatory adverse events. This poses challenges for treating SCD patients with BRAF/MEKi, and fever in these patients should be treated as a medical emergency. Proper HU treatment can help manage SCD patients undergoing BRAF/MEKi therapy.
THERAPEUTIC ADVANCES IN HEMATOLOGY
(2023)
Article
Hematology
Vasiliki Papadopoulou, Jacqueline Schoumans, Valentin Basset, Francoise Solly, Jerome Pasquier, Sabine Blum, Olivier Spertini
Summary: Objective IDH1/2 mutations, intervening in epigenetic procedures, are frequently encountered in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Knowledge of the genetics, immunophenotypes, and mutational kinetics of IDH1/2-mutated AML can contribute to the understanding of AML clonal architecture and inform therapeutics and monitoring.